Our immediate focus: Geographic Atrophy (dry macular degeneration), currently with no licensed treatment

Our immediate focus: Geographic Atrophy (dry macular degeneration), currently with no licensed treatment

Our lead product, CTx001, is in pre-clinical development for the localised treatment of Geographic Atrophy (‘dry’ age-related macular degeneration). In addition, we are developing therapeutics that are aimed at systemic modulation of the complement system.

We anticipate that these assets will meet the needs of a wide range of patients with complement-mediated disease.

Identified and corrected: flaws in other previous Complement-related approaches to treating Geographic Atrophy

The flaws we have identified have prevented these other therapies from delivering their intended effects.

In developing our own approaches, we have carefully analysed all aspects of the Complement System, investigated where therapies to date have fallen down and explored how we should avoid the flaws we have identified.

Core Technology Facility
46 Grafton Street
Manchester
M13 9NT
United Kingdom

Created by HTP Digital